133 related articles for article (PubMed ID: 15380186)
1. Simplified analogs of bryostatin with anticancer activity display greater potency for translocation of PKCdelta-GFP.
Baryza JL; Brenner SE; Craske ML; Meyer T; Wender PA
Chem Biol; 2004 Sep; 11(9):1261-7. PubMed ID: 15380186
[TBL] [Abstract][Full Text] [Related]
2. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1.
Szallasi Z; Du L; Levine R; Lewin NE; Nguyen PN; Williams MD; Pettit GR; Blumberg PM
Cancer Res; 1996 May; 56(9):2105-11. PubMed ID: 8616857
[TBL] [Abstract][Full Text] [Related]
3. Structural modifications of bryostatin 2.
Pettit GR; Sengupta D; Blumberg PM; Lewin NE; Schmidt JM; Kraft AS
Anticancer Drug Des; 1992 Apr; 7(2):101-14. PubMed ID: 1575884
[TBL] [Abstract][Full Text] [Related]
4. Identification of a tunable site in bryostatin analogs: C20 Bryologs through late stage diversification.
Wender PA; Baryza JL
Org Lett; 2005 Mar; 7(6):1177-80. PubMed ID: 15760168
[TBL] [Abstract][Full Text] [Related]
5. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity.
Berkow RL; Schlabach L; Dodson R; Benjamin WH; Pettit GR; Rustagi P; Kraft AS
Cancer Res; 1993 Jun; 53(12):2810-5. PubMed ID: 8504423
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of a simplified bryostatin C-ring analogue that binds to the CRD2 of human PKC-alpha and construction of a novel BC-analogue by an unusual Julia olefination process.
Hale KJ; Frigerio M; Manaviazar S; Hummersone MG; Fillingham IJ; Barsukov IG; Damblon CF; Gescher A; Roberts GC
Org Lett; 2003 Feb; 5(4):499-502. PubMed ID: 12583753
[TBL] [Abstract][Full Text] [Related]
7. Total synthesis and initial biological evaluation of new B-ring-modified bryostatin analogs.
Wender PA; Horan JC; Verma VA
Org Lett; 2006 Nov; 8(23):5299-302. PubMed ID: 17078702
[TBL] [Abstract][Full Text] [Related]
8. The design, computer modeling, solution structure, and biological evaluation of synthetic analogs of bryostatin 1.
Wender PA; DeBrabander J; Harran PG; Jimenez JM; Koehler MF; Lippa B; Park CM; Siedenbiedel C; Pettit GR
Proc Natl Acad Sci U S A; 1998 Jun; 95(12):6624-9. PubMed ID: 9618462
[TBL] [Abstract][Full Text] [Related]
9. Role of the A-ring of bryostatin analogues in PKC binding: synthesis and initial biological evaluation of new A-ring-modified bryologs.
Wender PA; Clarke MO; Horan JC
Org Lett; 2005 May; 7(10):1995-8. PubMed ID: 15876038
[TBL] [Abstract][Full Text] [Related]
10. A simple analogue of tumor-promoting aplysiatoxin is an antineoplastic agent rather than a tumor promoter: development of a synthetically accessible protein kinase C activator with bryostatin-like activity.
Nakagawa Y; Yanagita RC; Hamada N; Murakami A; Takahashi H; Saito N; Nagai H; Irie K
J Am Chem Soc; 2009 Jun; 131(22):7573-9. PubMed ID: 19449873
[TBL] [Abstract][Full Text] [Related]
11. Biological activity of 26-succinylbryostatin 1.
Bignami GS; Wagner F; Grothaus PG; Rustagi P; Davis DE; Kraft AS
Biochim Biophys Acta; 1996 Jul; 1312(3):197-206. PubMed ID: 8703988
[TBL] [Abstract][Full Text] [Related]
12. The novel cytotoxic sponge metabolite peloruside A, structurally similar to bryostatin-1, has unique bioactivity independent of protein kinase C.
Hood KA; Bäckström BT; West LM; Northcote PT; Berridge MV; Miller JH
Anticancer Drug Des; 2001; 16(2-3):155-66. PubMed ID: 11962513
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of a potent, PKC selective, B-ring analog of bryostatin.
Wender PA; Verma VA
Org Lett; 2006 Apr; 8(9):1893-6. PubMed ID: 16623578
[TBL] [Abstract][Full Text] [Related]
14. Function oriented synthesis: the design, synthesis, PKC binding and translocation activity of a new bryostatin analog.
Wender PA; Baryza JL; Brenner SE; Clarke MO; Craske ML; Horan JC; Meyer T
Curr Drug Discov Technol; 2004 Jan; 1(1):1-11. PubMed ID: 16472215
[TBL] [Abstract][Full Text] [Related]
15. Clinical development of anticancer agents from natural products.
Parkinson DR; Arbuck SG; Moore T; Pluda JM; Christian MC
Stem Cells; 1994 Jan; 12(1):30-43. PubMed ID: 7908243
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 TAT protein transduction domain mediates enhancement of enzyme prodrug cancer gene therapy in vitro: a study with TAT-TK-GFP triple fusion construct.
Meriläinen O; Hakkarainen T; Wahlfors T; Pellinen R; Wahlfors J
Int J Oncol; 2005 Jul; 27(1):203-8. PubMed ID: 15942661
[TBL] [Abstract][Full Text] [Related]
17. Development of a microscopy-based assay for protein kinase Czeta activation in human breast cancer cells.
Zhao C; Cai M; Zhang Y; Liu Y; Sun R; Zhang N
Anal Biochem; 2007 Mar; 362(1):8-15. PubMed ID: 17240347
[TBL] [Abstract][Full Text] [Related]
18. The practical synthesis of a novel and highly potent analogue of bryostatin.
Wender PA; Baryza JL; Bennett CE; Bi FC; Brenner SE; Clarke MO; Horan JC; Kan C; Lacôte E; Lippa B; Nell PG; Turner TM
J Am Chem Soc; 2002 Nov; 124(46):13648-9. PubMed ID: 12431074
[TBL] [Abstract][Full Text] [Related]
19. Preclinical and Clinical Studies on Bryostatins, A Class of Marine-Derived Protein Kinase C Modulators: A Mini-Review.
Raghuvanshi R; Bharate SB
Curr Top Med Chem; 2020; 20(12):1124-1135. PubMed ID: 32209043
[TBL] [Abstract][Full Text] [Related]
20. Synthetic bryostatin analogues activate the RasGRP1 signaling pathway.
Stone JC; Stang SL; Zheng Y; Dower NA; Brenner SE; Baryza JL; Wender PA
J Med Chem; 2004 Dec; 47(26):6638-44. PubMed ID: 15588099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
